Lupin Expands Vizag Facility with New Oncology Manufacturing Unit

Lupin Manufacturing Solutions (LMS), a fully owned subsidiary of a multinational pharmaceutical company Lupin, has also established a separate Oncology Block in its Vizag plant in India.

This high-capacity unit will increase the end-to-end CDMO service of High Potent Active Pharmaceutical Ingredients (HPAPIs) and fulfill the rising international need to develop and produce oncology drugs.

Spanning 4,270 square meters, the newly commissioned facility is equipped with 20 reactors ranging from 250L to 2000L, along with over 20 isolators and advanced containment systems ensuring exposure levels of ≤0.05 g/m³.

Also Read: How Pharma Authentication Tech Enhances ROI and Safety

 The setup is designed to handle complex, high-potent molecules safely and efficiently, meeting international safety and quality standards.

The block has scalable output, with a minimum batch size of 1?kg to 35?kg, and tight environmental regulation maintaining temperatures under 25 Degree Celsius and humidity under 45 per cent Relative Humidity. These characteristics can be used to easily move the initial investigation to commercial manufacturing.

The block can also provide clients with all phases of the oncology development cycle, including preclinical research and the full-scale production, which will enhance the reputation of LMS as the global partner of high-potent manufacturing. LMS strengthens its oncology portfolio and promotes the position of India in highly developed pharmaceutical manufacturing by increasing its specialized manufacturing base, which highlights the great impulse to the growth of the life-sciences sector based on innovations.